Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Lasmiditan
Drug: Topiramate

First Posted Date: 2017-10-12

Last Posted Date: 2019-11-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT03308669

Locations: 🇺🇸
Covance Madison CRU, Madison, Wisconsin, United States

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

Phase 2

Completed

Conditions: Lewy Body Dementia

Interventions: Drug: LY3154207
Drug: Placebo

First Posted Date: 2017-10-10

Last Posted Date: 2021-07-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 344

Registration Number: NCT03305809

Locations: 🇺🇸
University of Arizona Health Sciences, Tucson, Arizona, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
Christiana Care Health Service, Newark, Delaware, United States

and more 73 locations

A Study of LY900014 in Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY900014
Drug: Insulin Lispro

First Posted Date: 2017-10-10

Last Posted Date: 2020-05-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 38

Registration Number: NCT03305822

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Nordrhein-Westfalen, Germany

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

Phase 1

Completed

Conditions: Recreational Drug Use
Prescription Drug Abuse (Not Dependent)

Interventions: Drug: Placebo
Drug: Lasmiditan
Drug: Alprazolam

First Posted Date: 2017-09-18

Last Posted Date: 2020-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 96

Registration Number: NCT03286218

Locations: 🇺🇸
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States

A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY900014
Drug: Insulin Lispro

First Posted Date: 2017-09-18

Last Posted Date: 2020-05-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT03286751

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Olaratumab
Drug: Doxorubicin
Drug: Ifosfamide
Drug: Mesna

First Posted Date: 2017-09-14

Last Posted Date: 2020-09-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT03283696

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Miami School of Medicine, Miami, Florida, United States
🇩🇪
Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany

and more 3 locations

A Study of Lasmiditan and Propranolol in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lasmiditan
Drug: Propranolol

First Posted Date: 2017-09-01

Last Posted Date: 2019-12-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 44

Registration Number: NCT03270644

Locations: 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Biological: Pegilodecakin

First Posted Date: 2017-08-30

Last Posted Date: 2019-04-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT03267732

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

A Study of Multiple Doses of Lasmiditan in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Probe Drug Cocktail
Drug: Placebo
Drug: Lasmiditan

First Posted Date: 2017-08-16

Last Posted Date: 2020-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT03252015

Locations: 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States

A Study of Lasmiditan in Participants With Migraine

Phase 1

Completed

Conditions: Migraine Disorders

Interventions: Drug: Lasmiditan

First Posted Date: 2017-08-14

Last Posted Date: 2019-12-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT03247790

Locations: 🇺🇸
eStudySite, San Diego, California, United States
🇺🇸
AGA Clinical Trials, Hialeah, Florida, United States
🇺🇸
Meridien Research Inc., Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy